menu
    • menu

    Company profile for Oncopeptides

    NEW Drugs in Dev: 4
    Coral

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Oncopeptides is a pharmaceutical company focused on the development of therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen in multiple myeloma. Melflufen is a novel peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells. Melflufen is currently being tested in four clinical studies including the pivotal phase 2 HO...
    Oncopeptides is a pharmaceutical company focused on the development of therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen in multiple myeloma. Melflufen is a novel peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells. Melflufen is currently being tested in four clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study, the phase 1/2 combination study ANCHOR and the phase 2 Study BRIDGE.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    OncopeptidesSweden Flag
    Country
    Country
    Sweden
    Address
    Address
    Luntmakargatan 46, vån 7 SE-111 37 Stockholm
    Telephone
    Telephone
    +46 8 615 20 40
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.oncopeptides.com/en
    Linkedin
    Linkedin
    https://www.linkedin.com/company/oncopeptides-ab
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Study Backs Pepaxti in RRMM Patients with Reduced Kidney Function
    Study Backs Pepaxti in RRMM Patients with Reduced Kidney Function

    21 May 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-05-21/study-confirms-use-of-pepaxti-in-a-broader-population-with-strong-data-in-the-50-of-rrmm-patients-that-suffer-from-reduced-kidney-function

    PHARMIWEB
    21 May 2026
    Share Share
    AACR 2026 Will Showcase Novel NK Engager Data
    AACR 2026 Will Showcase Novel NK Engager Data

    14 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-14/preclinical-data-on-novel-nk-cell-engager-to-be-presented-at-the-aacr-annual-meeting-2026

    PHARMIWEB
    14 Apr 2026
    Share Share
    Expert Consensus Supports Use of Pepaxti in Myeloma
    Expert Consensus Supports Use of Pepaxti in Myeloma

    11 Nov 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-11-11/annals-of-hematology-expert-consensus-supports-use-of-pepaxti-in-myeloma

    PHARMIWEB
    11 Nov 2025
    Share Share
    Oncopeptides Collaborates With Top Universities On NK Cell
    Oncopeptides Collaborates With Top Universities On NK Cell

    04 Nov 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-11-04/research-by-top-universities-together-with-oncopeptides-on-nk-cell-engagers-to-be-presented-at-ash

    PHARMIWEB
    04 Nov 2025
    Share Share
    Oncopeptides Hosts Multiple Myeloma Experts at Capital Markets
    Oncopeptides Hosts Multiple Myeloma Experts at Capital Markets

    23 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-23/oncopeptides-to-host-capital-markets-update-featuring-leading-global-experts-in-multiple-myeloma

    PHARMIWEB
    23 Oct 2025
    Share Share
    Issue and re-purchase of class C shares for shareholder program
    Issue and re-purchase of class C shares for shareholder program

    27 Feb 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-02-27/issue-and-re-purchase-of-class-c-shares-for-shareholder-program

    PHARMAWEB
    27 Feb 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search